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Summary
 
We have previously demonstrated a role for Fas and Fas ligand (FasL) in the pathogenesis of ex-
perimental allergic encephalomyelitis (EAE). However, using an active induction paradigm we
could not distinguish between FasL expressed on activated CD4
 
1
 
 T cells from that expressed
on other inflammatory or resident central nervous system (CNS) cells. To address this issue, we
have conducted reciprocal adoptive transfer experiments of nontransgenic or myelin basic pro-
tein–specific T cell receptor transgenic wild-type, 
 
lpr
 
, or 
 
gld
 
 lymphocytes into congenic wild-
type, 
 
lpr
 
,
 
 
 
and 
 
gld 
 
hosts. We found that FasL expressed on donor cells is important for the devel-
opment of EAE, as FasL-deficient lymphocytes transfer attenuated disease. Furthermore, Fas
expressed in the recipient animals is important for the progression of EAE, as clinical signs of
disease in 
 
lpr
 
 recipients were dramatically attenuated after transfer of either wild-type or 
 
lpr
 
 T
cells. Surprisingly, these experiments also identified CNS cells as a source of functional FasL.
Host-derived FasL appears to be especially important in the recovery from EAE, as many 
 
gld
 
recipients of wild-type lymphocytes develop prolonged clinical signs of disease. Thus it appears
that FasL plays distinct roles in EAE during the initiation of and recovery from disease.
Key words: autoimmunity • inﬂammation • T cell regulation • demyelinating disease • 
apoptosis
 
E
 
xperimental allergic encephalomyelitis (EAE)
 
1
 
 is an ani-
mal model of the human demyelinating disease multiple
sclerosis (MS). EAE can be induced in several rodent species
by either active immunization with myelin components or
passive transfer of activated, myelin-specific CD4
 
1
 
 T cells (1,
2) of the Th1 (3, 4) but not Th2 subset into naive mice. The
histological hallmark of EAE is a perivascular infiltrate com-
prised primarily of macrophages and T lymphocytes, which
manifests itself clinically as a predictable course of ascending
paralysis. Although it is thought that MS and EAE are auto-
 
immune in nature, the precise target(s) and mechanism(s) of
myelin disruption remain unknown.
Fas (CD95/APO-1) and Fas ligand (FasL; CD95L) are type
I and type II transmembrane proteins and members of the
TNF/nerve growth factor receptor and TNF families of pro-
teins, respectively (5). Several recent studies have shown that
expression of Fas and its ligand are elevated in MS lesions,
implicating these molecules as potential effectors of this dis-
ease (6–8). Functional Fas is also expressed on myelin basic
protein (MBP)-specific T lymphocytes isolated from MS pa-
tients (9, 10), suggesting that Fas-mediated death could con-
tribute to the regulation of auto (central nervous system
[CNS])-reactive T cell expansion in this disease as well.
We (11) and others (12, 13) have demonstrated that de-
fective expression of Fas (
 
lpr
 
) or FasL (
 
gld
 
) dramatically ame-
liorates the clinical signs of MBP- or myelin oligodendrocyte
glycoprotein–induced EAE in B10.PL or C57BL/6 mice,
respectively. The mitigation of disease by the 
 
lpr
 
 and 
 
gld
 
mutations does not result from abnormalities in the pro-
duction of MBP-specific Th1 T cells, the development of a
Th1-mediated immune response in vivo, or the infiltration
of inflammatory cells into the CNS (11). These data impli-
cated a role for Fas in the pathogenesis of EAE. However,
using an active induction paradigm we could not distin-
guish between FasL expressed on activated CD4
 
1
 
 T cells
from that expressed on other inflammatory or resident CNS
cells. In addition, any Fas-dependent regulatory function in-
volved in the remission of actively induced EAE would have
been masked by the dominant inhibitory effect of the 
 
lpr
 
and 
 
gld
 
 mutations during the initiation and early progres-
sion of disease.
In this paper we have used an adoptive transfer model of
EAE to address these issues in animals deficient in Fas or
 
1
 
Abbreviations used in this paper:
 
 B6, C57BL/6; CNS, central nervous sys-
tem; EAE, experimental allergic encephalomyelitis; FasL, Fas ligand;
GVHD, graft-versus-host disease; MBP, myelin basic protein; MS, multi-
ple sclerosis; TUNEL, TdT-mediated dUTP nick-end labeling. 
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FasL. The data indicate that Fas expression in the host con-
tributes to the pathogenesis of EAE. Furthermore, these
data indicate that FasL is playing a dual role as an effector
and as a regulator of disease via its interactions with Fas ex-
pressed on CNS elements and on infiltrating T lympho-
cytes, respectively.
 
Materials and Methods
 
Antigens and Animals.
 
MBP was prepared from guinea pig spinal
cords (Keystone Biologicals) as previously described (14). C57BL/6
(B6, H-2
 
b
 
), B6Smn.MRL-
 
Fas
 
lpr
 
 (B6.
 
lpr
 
, H-2
 
b
 
), B6Smn.C3H-
 
Fasl
 
gld
 
(B6.
 
gld
 
, H-2
 
b
 
), and B10.PL (H-2
 
u
 
) mice were obtained from The
Jackson Laboratory or produced in our own breeding colony from
breeding stock obtained from The Jackson Laboratory. The con-
genic B10.PL.
 
Fas
 
lpr
 
 and B10.PL.
 
Fasl
 
gld
 
 mice were produced in our
facility by backcrossing the mutations from the C57BL/6 back-
ground (B6.
 
lpr
 
 or B6.
 
gld
 
) onto B10.PL for six generations. Be-
cause C57BL/10 and C57BL/6 are closely related substrains (15,
16) and neither mutation is linked to the MHC locus (MHC
 
 5
 
chromosome 17, 
 
lpr
 
 5 
 
chromosome 19, 
 
gld
 
 5 
 
chromosome 1),
transfer of the mutations from congenic C57BL/6 animals to
C57BL/10.PL produces essentially congenic mutations on the
B10.PL background. Mutant animals backcrossed one to six gener-
ations have behaved similarly in our active induction experiments
(i.e., developed ameliorated clinical signs of EAE compared with
B10.PL mice), indicating that the B10.PL.
 
Fas
 
lpr
 
 and B10.PL.
 
Fasl
 
gld
 
mice are essentially congenic with B10.PL animals. MBP-specific
TCR transgenic mice on a B10.PL background (H-2
 
u
 
; MBP-1;
provided by Hugh McDevitt, Stanford University, CA) (17) were
crossed with B10.PL.
 
Fas
 
lpr
 
 and B10.PL.
 
Fasl
 
gld
 
 animals to produce
MBP-specific TCR transgenic mice homozygous for the 
 
lpr
 
 or 
 
gld
 
allele. Animals were screened for the MBP-specific TCR transgene
by dual labeling PBLs with 10 
 
m
 
g/ml FITC-conjugated anti-CD4
(H129.19; PharMingen) and biotinylated anti-V
 
b
 
8.1,8.2 (MR5-2;
PharMingen). PE-conjugated streptavidin (Southern Biotechnol-
ogy Associates) was used as secondary reagent. Unless indicated
otherwise, all experiments were begun with animals that were 6–8
wk of age and, in most instances, were completed before they had
reached 12 wk of age. Animals were housed under specific patho-
gen–free conditions at the Washington University School of Med-
icine facility according to Association for Assessment and Accredi-
tation of Laboratory Animal Care guidelines.
 
Adoptive Transfer of EAE.
 
Draining lymph nodes and spleens
were removed from donor mice 10–12 d after subcutaneous im-
munization with 400 
 
m
 
g gpMBP and 60 
 
m
 
g 
 
Mycobacterium tuber-
culosis
 
 (H37RA; Difco Labs.) in IFA (Calbiochem). Single cell
suspensions were treated with red blood cell lysis buffer (Sigma
Chemical Co.) and washed, and 4–5 
 
3
 
 10
 
6
 
 cells/ml were cul-
tured with 20–25 
 
m
 
g/ml gpMBP in 6-well plates for 4 d. On
day 4, cells were harvested and resuspended in HBSS. 5–8 
 
3
 
 10
 
7
 
viable cells were injected intravenously into 8-wk-old recipients
(H-2
 
u
 
) that had been sublethally irradiated (350 rads) 3–6 h previ-
ously. Recipient mice were also administered 200 ng pertussis
toxin (List Biologicals) intravenously on days 0, 3, and 7. Cells
isolated from donor mice immunized with CFA alone were not
viable after 4 d in culture with gpMBP and therefore were not
transferred. Instead, control mice were sublethally irradiated and
administered all three doses of pertussis toxin. For the transfer of
MBP-specific TCR transgenic cells, lymph nodes and spleens
were removed from transgenic mice and single cell suspensions
were depleted of red blood cells and cultured for 2 d in 50 ml of
 
medium containing 10 
 
m
 
g/ml gpMBP in a T75 flask. On the
second day, one-half of the medium was removed, replaced with
fresh medium plus antigen, and incubated for an additional 2 d.
Cells were harvested and resuspended in HBSS. 10
 
7
 
 viable cells
were injected intravenously into 6-8 wk old recipients (H-2
 
u
 
)
that had been sublethally irradiated (450R) 3-6 h previously. Per-
tussis toxin was not administered. Clinical signs of disease were
monitored daily and were graded as follows: 0,
 
 
 
normal; 0.5,
 
 
 
par-
tial loss of tail tonicity, assessed by inability to curl distal end of tail;
1,
 
 
 
complete loss of tail tonicity; 2,
 
 
 
mild to moderate hindlimb weak-
ness or ataxia; 3,
 
 
 
partial hindlimb paralysis; 4,
 
 
 
complete hindlimb pa-
ralysis; 5,
 
 
 
moribund. Moribund animals were killed. Aliquots of the
cells transferred were stained with 10 
 
m
 
g/ml FITC-conjugated
anti-CD4, anti-Lyt-2 (Becton Dickinson) or anti-CD19 (1D3;
PharMingen), purified anti-CD11b (M1/70; PharMingen), and/
or biotinylated anti-V
 
b
 
8.1, 8.2. FITC-conjugated goat anti–rat
(1:40), and PE-conjugated streptavidin (1:300) were used as sec-
ondary reagents (Southern Biotechnology Associates).
 
Histological Analysis.
 
CNS tissues removed from mice per-
fused with buffered 2.5% glutaraldehyde were postfixed in 1%
osmium tetroxide (Electron Microscopy Sciences), dehydrated
through graded alcohols and embedded in EMBED 812 (EMS)
as previously described (18). 1 
 
m
 
m sections taken from each level
of the CNS (optic nerves, cerebrum, cerebellum, brainstem, and
cervical, thoracic, lumbar, and sacral spinal cord regions) were
placed on glass slides, stained with toluidine blue, and assessed
blindly using a published scoring system from 0 to 5 for inflam-
mation, demyelination, and axonal necrosis (19).
 
Adoptive Transfer of B6 anti-B10.PL Cells.
 
Splenocytes from B6
mice were cultured for 5 d with an equal number of irradiated
B10.PL splenocytes in 50 ml of medium in a T75 flask (
 
z
 
3–6 
 
3
 
10
 
8
 
 B6 splenocytes/flask). On day 5, viable cells were recovered
by Ficoll-Histopaque-1077 (Sigma Chemical Co.) density centri-
fugation, washed twice, and resuspended in HBSS. 5 
 
3
 
 10
 
7
 
 via-
ble cells were injected intravenously into 8-wk-old B10.PL or
B10.PL.
 
Fas
 
lpr
 
 recipients that had been sublethally irradiated (350
rads) 3–6 h previously. Control mice were sublethally irradi-
ated, but were not given B6 anti-B10.PL cells. On days 1, 3, and
5 after transfer, control and injected animals were killed for anal-
ysis. Tissue samples from spleen, liver, lung, and small intestine
were removed from mice and embedded in OCT (Miles, Inc.)
for immunohistochemical analysis.
 
Immunohistochemistry.
 
9-
 
m
 
M frozen sections were placed on
Superfrost Plus slides (Fisher Scientific Co.) and fixed in acetone
for 10 min. Sections were stained with the appropriate Vectastain
ABC-Elite kit (Vector Labs, Inc.) according to the manufac-
turer’s instructions. In brief, sections were blocked with normal
serum for 30 min and then incubated with primary antibody at
4
 
8
 
C overnight. Sections were washed twice and endogenous per-
oxidase activity was blocked with 0.3% hydrogen peroxide in
methanol for 30 min. Slides were then incubated with diluted
ABC reagent for 30 min. Peroxidase reaction was developed us-
ing the VIP Vectastain substrate kit. Antibodies and dilutions
used were biotinylated anti-K
 
b
 
 (1:50; PharMingen) and biotiny-
lated anti-L
 
d
 
 (30-5-7) (1:100; provided by Dr. Ted Hansen,
Washington University, St. Louis, MO).
 
TUNEL Assay and Fluorescent Immunolabeling.
 
Mice were anes-
thetized with methoxyfluorane and perfused with saline. CNS
tissues were removed and embedded in OCT. 9-
 
m
 
M frozen sec-
tions were placed on Superfrost Plus slides, fixed in 1% para-
formaldehyde for 5 min, and permeabilized in 100% ethanol for
5 min. TUNEL (TdT-mediated dUTP nick-end labeling) stain-
ing was conducted using a modification of a previously published 
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protocol (20). In brief, slides were incubated with 0.3 U/
 
m
 
l termi-
nal transferase (Boehringer Mannheim) and Cy3-labeled dUTP
(Amersham Pharmacia Biotech) in TdT buffer (30 mM Tris HCl,
pH 7.3, 140 mM sodium cacodylate, and 1 mM cobalt chloride)
at 37
 
8
 
C for 1 h. The reaction was terminated in buffer containing
300 mM sodium chloride and 30 mM sodium citrate. After
washing in PBS, sections were blocked with normal rabbit serum
for 30 min and then incubated with either anti-CD4 (GK1.5;
1:1,000; Becton Dickinson) or anti-CD11b (M1/70; 1:10,000;
PharMingen) at 4
 
8
 
C overnight. Slides were washed twice and in-
cubated with biotinylated rabbit anti–rat secondary antibody
(1:200; Vector Labs) for 30 min. Endogenous peroxidase activity
was blocked with 1% hydrogen peroxide in methanol for 30 min.
Slides were then processed using the tyramide signal amplification
(TSA)-direct kit (NEN Life Sciences) according to the manufac-
turer’s instructions, counterstained with Hoechst 33258 (Poly-
sciences, Inc.) and mounted in Fluoromount-G (Southern Bio-
technology Associates). TUNEL
 
1
 
 cells, CD4
 
1
 
 or CD11b
 
1
 
 cells,
and double-labeled cells were counted in two to four inflamma-
tory lesions per mouse using two coded slides per lesion. For
some experiments, “nests” of 
 
.
 
10 immediately adjacent CD4
 
1
 
cells were counted in four to five representative lower spinal cord
cross-sections per mouse.
 
Results
 
We (11) and others (12, 13) have previously shown that
both the 
 
lpr
 
 and 
 
gld
 
 mutations ameliorate the clinical signs
of EAE actively induced in H-2
 
u
 
 or H-2
 
b
 
 mice by immuni-
zation with MBP or myelin oligodendrocyte glycoprotein,
respectively. We have also demonstrated that these muta-
tions do not affect the production of MBP-specific Th1 T
cells, the development of a Th1-mediated immune re-
sponse in vivo, or the infiltration of inflammatory cells into
the CNS (11). These data indicated that Fas and its ligand
are important for the progression of clinical signs of EAE.
We hypothesized that FasL
 
1
 
 myelin-reactive lymphocytes
contributed to the pathogenesis of EAE by lysing Fas-
expressing targets in the CNS. However, our active induc-
tion experiments could not distinguish FasL expressed on
activated, myelin-specific CD4
 
1
 
 T cells from that expressed
on other inflammatory or resident CNS cells. Furthermore,
because the mitigation of EAE was the dominant effect of
the 
 
lpr
 
 and 
 
gld
 
 mutations, we were unable to determine
whether a Fas-mediated lytic interaction might also be
contributing
 
 
 
to the recovery from actively induced disease.
Therefore, to further examine the role of Fas and its
ligand in EAE, we conducted adoptive transfer experiments
of myelin-reactive wild-type, 
 
lpr
 
, or 
 
gld
 
 lymphocytes into
congenic wild-type, 
 
lpr
 
,
 
 
 
and gld hosts (H-2u). In our initial
experiments, conventional (polyclonal) MBP-specific lym-
phocytes isolated from primed animals and cultured in
MBP for 4 d were used as donor cells. Both MBP-specific
cells and pertussis toxin were required for recipient animals
to develop EAE. To complete the reciprocal transfers, it
was necessary to introduce the mutations (especially lpr)
onto an MBP-specific TCR transgenic mouse. TCR trans-
genic wild-type, lpr, and gld cells from unimmunized mice
responded equally well to in vitro stimulation with MBP,
and more vigorously compared with the nontransgenic
cells (data not shown). These cultures contained 62–78%
CD41 and 2–5% CD81 T lymphocytes, 12–18% B cells, and
,5% macrophages.
Fas-mediated Lysis Is Important in the Initiation/Early 
Progression of EAE
Host-derived Fas Contributes to the Pathogenesis of EAE.
In our initial experiments, conventional MBP-specific
wild-type (B10.PL) cells were adoptively transferred into
congenic wild-type, lpr, and gld hosts (Fig. 1 and Table I).
Clinical signs of disease consistently appeared 20–30 d after
transfer in recipients of all three genotypes. 88% of the
wild-type animals developed clinical signs of EAE, with a
peak disease severity corresponding to partial hindlimb pa-
ralysis (3.0 6 0.91; median 5 3). On the other hand, lpr re-
cipients were quite resistant to the development of EAE,
with only 12% of the animals exhibiting clinical disease.
The two lpr mice that did develop clinical signs of EAE de-
veloped very mild disease corresponding to tail paralysis
(grades 1 and 2; P 5 0.032 versus wild-type). These data
are consistent with our previous study in which the lpr mu-
tation mitigated the development of actively induced EAE.
In contrast to our previous study using an active induction
paradigm, gld recipients of adoptively transferred wild-type
lymphocytes were overall highly susceptible to disease,
with an incidence of 75% and a mean peak disease severity
similar to that observed in wild-type recipients (3.0 6 1.1;
median 5 2.25). However, unlike in the wild-type recipi-
ents, in which all animals developing clinical signs of EAE
progressed to clinical scores of 2–4, the severity of EAE in
gld animals was highly variable. Some (9 out of 28) gld re-
cipients developed only mild clinical signs of EAE (grade
0–1.5), similar to that observed in the lpr recipients. How-
Figure 1. Peak clinical scores of EAE adoptively transferred with wild-
type lymphocytes vary with recipient genotype. 5–8 3 107 conventional
(i.e., nontransgenic) wild-type lymphocytes were injected intravenously
into sublethally irradiated (350 rads) B10.PL (WT) or congenic lpr and gld
recipients along with 200 ng pertussis toxin. Animals were given two ad-
ditional injections of pertussis toxin on days 3 and 7. Clinical signs were
monitored daily and graded on a scale from 0 to 5 as described in Materi-
als and Methods. Data were pooled from four experiments.1198 Dual Role for FasL in Experimental Allergic Encephalomyelitis
ever, most (17 out of 28) gld recipients exhibited clinical
scores of grades 2 to 4, and two mice progressed to the
most severe stage of disease (grade 5).
The adoptive transfer of MBP-specific TCR transgenic
wild-type lymphocytes into wild-type and congenic lpr and
gld hosts confirmed the results obtained when conventional
wild-type lymphocytes were transferred (Fig. 2 A and Ta-
ble II). lpr recipients were resistant to the development of
clinical signs of EAE transferred by transgenic wild-type
cells. In contrast, all of the wild-type and gld animals devel-
oped clinical signs of EAE z2 wk after cell transfer, with
peak clinical scores corresponding to moderate hindlimb
weakness (wild-type, 2.1 6 0.97, median 5 2; gld, 2.4 6
0.78, median 5 2). Thus, the adoptive transfers of myelin-
reactive wild-type T cells demonstrate that Fas expressed
within the host (presumably in the CNS) plays an impor-
tant role in the pathogenesis of EAE.
Adoptively Transferred Lymphocytes Are Not Eliminated in
lpr Recipients. Having established that lpr recipients de-
velop only mild clinical signs of adoptively transferred
EAE, we asked whether this amelioration of disease was ac-
tually due to a paucity of Fas1 targets in the CNS, or if it
was simply because the lpr host lymphocytes, which are re-
ported to express elevated levels of FasL (21), were elimi-
nating the activated, Fas1 lymphocytes we transferred. We
were unable to unequivocally identify the donor lympho-
cytes in adoptive transfer experiments described above.
Therefore, 5 3 107 B6 anti-B10.PL cells (H-2b) from a 5-d
MLR were injected into sublethally irradiated wild-type or
lpr hosts (H-2u). Spleens were removed at various days after
transfer and stained for Ld, a marker of the H-2u haplotype,
and Kb, a marker of the donor cells. Fig. 3 shows spleen
sections removed from wild-type and lpr mice 3 d after
transfer. Comparable numbers of Kb-expressing cells were
detected in the T cell zones, but not follicles, of both wild-
type and lpr animals given donor cells. Spleens taken from
wild-type and lpr animals that were irradiated but did not
receive Kb-expressing cells showed staining for Ld, but not
Figure 2. Reciprocal adoptive transfers of MBP-specific TCR trans-
genic wild-type, lpr, or gld lymphocytes into B10.PL or congenic lpr and
gld mice. 107 activated, transgenic wild-type (A), lpr (B), or gld (C) lym-
phocytes were injected intravenously into sublethally irradiated (450 rads)
B10.PL or congenic lpr and gld recipients. Clinical signs were monitored
daily and graded on a scale from 0 to 5 as described in Materials and
Methods. Data were pooled from two separate experiments for each type
of donor cell.
Table I. Adoptive Transfers of Nontransgenic Wild-type or gld 
Lymphocytes into B10.PL and Congenic lpr and gld Mice*
Recipient genotype
Incidence
of clinical
signs (%)
Mean peak
clinical
score
Mean peak
disease
severity
Wild-type donor cells
B10.PL 22/25 (88) 2.3 6 1.5 3.0 6 0.91
lpr/lpr 2/17 (12) 0.16 6 0.50‡ 1.5 6 0.71‡
gld/gld 21/28 (75) 2.0 6 1.7 3.0 6 1.1
gld donor cells
B10.PL 4/18 (22) 0.36 6 0.72§ 1.6 6 0.48§
lpr/lpr 0/11 (0) 0 NA
gld/gld 4/15 (27) 0.90 6 1.6i 3.4 6 0.75¶
*5–8 3 107 wild-type or gld lymphocytes were injected intravenously
into sublethally irradiated (350 rads) B10.PL or congenic lpr and gld re-
cipients along with 200 ng pertussis toxin. Animals were given two ad-
ditional injections of pertussis toxin on days 3 and 7. Clinical signs were
monitored daily and graded on a scale from 0 to 5 as described in Mate-
rials and Methods. Data were pooled from two (gld donors) or four
(wild-type donors) experiments.
‡Mean peak clinical score, P 5 4.81 3 1027; mean peak disease sever-
ity (only includes animals with grade 1 or higher), P 5 0.032 (versus
B10.PL).
§Mean peak clinical score, P 5 9.24 3 1026; mean peak disease sever-
ity P 5 0.0066 (versus B10.PL recipients of wild-type cells).
iP 5 0.038 versus gld/gld recipients of wild-type cells.
¶P 5 0.0077 versus B10.PL.1199 Sabelko-Downes et al.
Kb (data not shown). 5 d after transfer, donor cells were re-
duced to a similar degree in spleens of both wild-type and
lpr recipients compared with day 3 levels (data not shown).
Lpr recipients of conventional, nontransgenic lympho-
cytes were monitored for clinical signs of disease for the
duration of each adoptive transfer experiment and therefore
were not examined for histological signs of EAE. How-
ever, the fact that some lpr hosts did develop clinical signs
of EAE suggests that the mutation does not preclude the
infiltration of cells into the CNS. Lpr recipients of MBP-
specific TCR transgenic wild-type lymphocytes (see below)
were examined histologically at 9 and 17 d after cell trans-
fer and found to have small infiltrates (grade 0.5–1) in the
CNS (data not shown). This is consistent with our previous
study in which we found Fas was not required for lympho-
cytes to infiltrate the CNS after active induction of EAE
(11). These data indicate that the lpr hosts are not abnor-
mally eliminating the adoptively transferred lymphocytes.
Thus, the lack of EAE we have observed in lpr recipients is
probably due to a role for host-derived Fas that is impor-
tant for the progression of severe disease.
Fas-deficient (lpr) MBP-specific TCR Transgenic Lymphocytes
Transfer EAE to Wild-type and gld, but Not lpr Recipients.
The adoptive transfer of nontransgenic lpr lymphocytes led
to the development of a lethal graft-versus-host disease
(GVHD) in many of the wild-type recipient animals before
the onset of clinical signs of EAE (data not shown). We rea-
soned that skewing the T cell repertoire to a predominantly
MBP-specific CD41 T cell population would prevent the
transfer of GVHD in our adoptive transfer experiments,
and thus introduced the lpr mutation onto an MBP-specific
TCR transgenic mouse. Wild-type and gld recipients of
transgenic  lpr lymphocytes did not develop GVHD, but did
develop clinical signs of EAE z2 wk after cell transfer. The
incidence of clinical disease induced by lpr donor cells was
lower (8 out of 14; 57%) than that induced by wild-type
lymphocytes (14 out of 14; 100%) after transfer into wild-
type recipients (Fig. 2 B and Table II). In those wild-type
recipients of transgenic lpr cells that developed EAE, the
peak disease severity corresponded to moderate hindlimb
weakness (2.3 6 0.70; median 5 2). Gld recipients were
more susceptible than wild-type hosts to disease induced by
transgenic lpr cells, with 92% developing clinical signs of
EAE. The severity of EAE induced by the transfer of trans-
genic lpr cells into gld recipients was highly variable. The
mean peak disease severity of gld recipients was 2.3 6 0.87
(median 5 2).
We also examined the induction and progression of adop-
tively transferred EAE in the complete absence of Fas by
transferring Fas-deficient (lpr) MBP-specific TCR transgenic
lymphocytes into lpr mice (Fig. 2 B and Table II). The inci-
dence of disease transferred by transgenic lpr donor cells into
lpr recipients was greatly reduced compared with the inci-
dence observed in wild-type and gld recipients, with only
12% (1 out of 8) of lpr recipient mice developing EAE of an
average peak clinical score of 0.12 6 0.35 (P 5 0.020 versus
wild-type; P 5 7.96 3 1025 versus gld). The onset of disease
in the one lpr recipient that developed clinical signs of EAE
occurred 24 d after cell transfer, which was slightly delayed
compared with disease onset in wild-type and gld recipients
of wild-type or lpr lymphocytes, and disease was mild (grade
1). Thus, Fas-deficient transgenic lpr lymphocytes were able
to transfer EAE into wild-type and gld, but not lpr recipients.
Furthermore, the disease that developed after the transfer of
lpr cells was similar in onset and severity to that observed
when wild-type lymphocytes were transferred.
Table II. Adoptive Transfers of MBP-specific TCR Transgenic 
Wild-type, lpr, or gld Lymphocytes in B10.PL and Congenic lpr
and gld Mice*
Recipient genotype
Incidence
of clinical
signs (%)
Mean peak
clinical
score
Mean peak
disease
severity
Wild-type donor cells
B10.PL 14/14 (100) 2.1 6 0.97 2.1 6 0.97
lpr/lpr 0/14 (0) 0 6 0‡ –
gld/gld 27/27 (100) 2.4 6 0.78 2.4 6 0.78
lpr donor cells
B10.PL 8/14 (57) 1.3 6 1.3 2.3 6 0.70
lpr/lpr 1/8 (12) 0.12 6 0.35§ 1
gld/gld 11/12 (92) 2.1 6 1.1 2.3 6 0.87
gld donor cells
B10.PL 2/16 (12) 0.44 6 1.2i 3.5 6 0.71
lpr/lpr 0/7 (0) 0 6 0–
gld/gld 1/16 (6) 0.13 6 0.52¶ 2
*107 activated, transgenic wild-type, lpr, or gld lymphocytes were in-
jected intravenously into sublethally irradiated (450 rads) B10.PL or
congenic lpr and gld recipients. Clinical signs were monitored daily and
graded on a scale from 0 to 5 as described in Materials and Methods.
Data were pooled from two separate experiments for each type of do-
nor cell.
‡P 5 9.4 3 1029 versus B10.PL.
§P 5 0.020 versus B10.PL.
iP 5 0.00023 versus B10.PL recipients of transgenic wild-type cells.
¶P 5 4.2 3 10213 versus gld/gld recipients of wild-type cells.
Figure 3. Adoptively transferred lymphocytes are not eliminated by lpr
recipients. B10.PL (A) or B10.PL.Faslpr (B and C) mice were sublethally
irradiated. 5 3 107 B6 anti-B10.PL cells from a 5-d MLR were injected
intravenously into some animals (A–C), with the remaining mice serving
as negative controls (data not shown). On day 3 after transfer, spleens
were removed and sections were stained for Ld (C) and Kb (A-B) to de-
tect host tissue and donor cells, respectively. Peroxidase reaction was de-
tected with VIP substrate, resulting in a pinkish/purple signal. No coun-
terstain was used. Region shown in B corresponds to that in C. Original
magnification: 3131.1200 Dual Role for FasL in Experimental Allergic Encephalomyelitis
In these experiments, the transgenic lpr lymphocytes
transferred could not have been eliminated by FasL1 cells
in the lpr recipients. Therefore it is highly unlikely that the
lack of EAE we have observed in the lpr recipient mice is
due to rejection of the donor lymphocytes. Instead, these
data demonstrate that Fas expressed by the recipient ani-
mals (presumably in the CNS) is an important determinant
for the pathogenesis of EAE.
FasL Expressed on Donor Lymphocytes Contributes to the De-
velopment of EAE. To determine the relative role of FasL
expressed by MBP-reactive T lymphocytes in the initiation
of EAE, conventional MBP-specific lymphocytes from gld
mice were adoptively transferred into congenic wild-type,
lpr, and gld recipients. The incidence of disease transferred
with MBP-reactive gld lymphocytes was rather low, with
only 22% of wild-type and 27% of gld animals developing
clinical signs of EAE (Table I). In the few wild-type and gld
recipients that exhibited clinical signs of EAE, the peak
disease severity corresponded to complete tail paralysis
(grades 1, 1.5, 2, 2) and partial to complete hindlimb paral-
ysis (grades 2.5, 3.5, 4, 4) for wild-type and gld recipients,
respectively. None of the 11 lpr mice that received gld lym-
phocytes developed clinical signs of disease over the dura-
tion of the experiments. These data suggest that FasL ex-
pressed on the donor lymphocyte population is important
for the initiation of the inflammatory cascade of events
leading to development of EAE. The apparent exacerba-
tion of clinical disease in the four gld recipients may reflect
an inability of those animals to control the expansion of in-
flammatory cells (see below) that have initiated the disease,
presumably through a Fas/FasL-independent mechanism.
Similar results were obtained when MBP-specific TCR
transgenic gld lymphocytes were transferred into wild-type
B10.PL and congenic lpr and gld hosts (Fig. 2 C and Table
II). None of the seven lpr recipients developed clinical signs
of EAE. The onset of disease in wild-type and gld recipients
of transgenic gld lymphocytes was slightly delayed (20 6 6),
but did not statistically differ from that seen in animals
receiving FasL-expressing cells. The incidence of disease
transferred with gld lymphocytes was low compared with
that transferred by transgenic wild-type lymphocytes. Only
12% of wild-type and 6% of gld hosts developed EAE with
average peak clinical scores of 0.44 6 1.2 and 0.13 6 0.52,
respectively.  Thus, the adoptive transfer of MBP-specific
TCR transgenic gld T cells further substantiates our conclu-
sion that FasL expressed on donor lymphocytes is important
for the initiation and/or progression of EAE.
Fas-dependent Lysis Is also Involved in the Remission
of EAE
Host-derived FasL Is Important in Recovery from EAE.
While analyzing the results from the transfer of conven-
tional wild-type lymphocytes into the various hosts, we
noticed that the duration of the clinical signs of EAE after
the onset of disease varied by genotype of the recipient.
Wild-type recipients recovered from the acute phase of
EAE, regardless of the severity of disease that had devel-
oped, with most entering complete remission within 30 d
of the onset of clinical signs (average 5 26 6 12 d) (Figs.
4 A and 5 A). Lpr recipients also recovered from acute EAE,
although the duration of disease (average 5 5 6 3 d) was
much shorter compared with that of wild-type recipients
and correlated with their mild disease severity rather than
their genotype (Fig. 4 C and data not shown). Surprisingly,
gld  recipients fell into two groups (Figs. 4 B and 5 B).
Those gld mice that developed mild disease (grade # 2)
were able to rapidly recover from the acute phase of EAE
(average 5 20 6 13 d compared with 31 6 13 d for wild-
type recipients [grade # 2]). In contrast, all gld recipients
that reached a clinical score greater than grade 2 developed
a more chronic disease, exhibiting clinical signs of EAE for
well over 35 d (average 5 50 6 14 d compared with 22 6
11 d for wild-type recipients greater than grade 2; P 5 2.4 3
1025). These data suggest that there is a source of FasL in
the recipient that is lacking in the gld mice and is important
in the recovery from severe disease.
A relationship between the severity of disease and dura-
tion of clinical signs of EAE in gld recipients similar to that
observed after transfer of conventional wild-type donor
Figure 4. Daily clinical scores of EAE for wild-type, lpr, and gld recipi-
ents of nontransgenic wild-type lymphocytes. EAE was induced as de-
scribed in Fig. 1. The daily clinical scores for representative wild-type (A),
lpr (C), and gld (B) recipient mice are shown. Animals represented with
open symbols were killed 23 or 68 d after transfer (arrows) for histological
analyses shown in Fig. 6.1201 Sabelko-Downes et al.
cells was also evident when disease was induced with TCR
transgenic cells. 82% (9 out of 11) of the wild-type recipi-
ents of transgenic wild-type cells recovered from the acute
phase of EAE within 15 d of the onset of clinical signs,
with the remaining 2 animals entering complete remission
within 20 d of clinical onset (average 5 12 6 5 d). In con-
trast, 57% (12 out of 21) of the gld recipients of wild-type
transgenic cells, and all of those exceeding a clinical score
of grade 2, exhibited clinical signs of EAE for .15 d (aver-
age 5 18 d 6 10; P 5 0.040). Likewise, when TCR trans-
genic lpr cells were transferred, only 2 out of 8 wild-type
recipients remained clinically affected for 15 d or more
(durations were 16 and 23 d). In contrast, 45% of gld recip-
ients (5 out of 11) exhibited clinical signs of EAE for 15 d
or more (durations were 15, 23, 30, 45, and 46 d, with the
latter two still affected at termination of experiment 56 d
after cell transfer). Thus, host-derived FasL can function in
the regulation of ongoing disease, possibly by eliminating
the infiltrating Fas1 T cells.
Fas-dependent Death of T Lymphocytes May Be Involved in
Recovery from EAE. The experiments above indicated that
severely affected gld recipients were unable to recover from
the acute phase of EAE as well as their wild-type counter-
parts. In an attempt to understand the differences between
acute and chronic disease, we decided to compare CNS le-
sions in wild-type and gld recipients of conventional wild-
type lymphocytes at both early/acute (day 23 after cell
transfer) and late/chronic (day 68 after cell transfer) stages of
disease (Fig. 6). Comparable levels of inflammation (grade 4)
were found in the lower spinal cords of a wild-type and gld
recipient during the acute phase of disease (Fig. 6, A and B).
Figure 5. Duration of clinical signs of adoptively transferred EAE is
prolonged in gld recipients. EAE was induced as described in Fig. 1. The
duration of clinical signs of EAE after the onset of disease versus the peak
clinical score for wild-type (A) and gld (B) recipients is shown. All lpr and
18 out of 21 wild-type recipients recovered from the acute phase of EAE
before the termination of the experiments at 90 d after cell transfer. In
contrast, 13 out of 21 gld recipients (62%) still exhibited clinical signs of
EAE on day 90 (P 5 0.00098). Animals killed for histological analyses or
for ethical reasons were not included in these analyses. Figure 6. Infiltration of the CNS during acute and chronic stages of
EAE in wild-type and gld hosts. EAE was induced as described in Fig. 1.
23 (A, B, D–F) and 68 (C and G–I) d after cell transfer, wild-type (A,
F, I) and gld (B–E, G, and H) animals were killed for histological and im-
munohistochemical analyses. (A–C) Anterior columns of lower spinal
cord sections stained with toluidine blue. A, wild-type mouse 23 d after
transfer; clinical score 5 4, inflammation score 5 4. B, gld mouse 23 d af-
ter transfer; clinical score 5 4, inflammation score 5 4. C, gld mouse 68 d
after transfer; clinical score 5 1, inflammation score 5 2. (D and G)
Lower spinal cord sections immunostained with anti-CD11b (macro-
phage/microglia marker; green). D, gld mouse 23 d after transfer; clinical
score 5 4. G, gld mouse 68 d after transfer; clinical score 5 2. (E, F, H,
and I) Lower spinal cord sections immunostained with anti-CD4 (green).
E, gld mouse 23 d after transfer; clinical score 5 4. The region shown in E
corresponds to that in D. F, wild-type mouse 23 d after transfer; clinical
score 5 4. H, gld mouse 68 d after transfer; clinical score 5 2. The region
shown in H corresponds to that in G. I, wild-type mouse 68 d after trans-
fer; clinical score 5 0. Original magnification: A–C, G, H, and I, 3131;
D, E, and F, 3262.1202 Dual Role for FasL in Experimental Allergic Encephalomyelitis
The infiltrates were comprised primarily of CD11b1 cells,
many of which were also TUNEL positive (Fig. 6 D and
data not shown). Roughly equal numbers of CD41 cells
were detected in inflammatory lesions from acutely affected
wild-type and gld mice, with z4% of them undergoing ap-
optotic cell death (i.e., TUNEL positive; Fig. 6, E and F,
and data not shown). The only potential difference observed
between wild-type and gld lesions at this stage of disease was
a more diffuse infiltration, especially of CD41 cells, in the
gld recipient (compare Fig. 6, A and F with B and E).
68 d after transfer, inflammation scores had diminished
somewhat in the wild-type animals that had clinically re-
covered from EAE and in the gld recipients that still exhib-
ited clinical signs of disease (wild-type, grade 1–2; gld,
grade 1.5–2.5) (Fig. 6 C and data not shown). The degree
of apoptotic cell death was greatly reduced in both wild-
type and gld lesions compared with that seen at the acute
stage of disease (data not shown). Wild-type lesions were
comprised of fewer CD11b1 cells that had a distribution
similar to that observed in acute lesions (data not shown). A
few, scattered CD41 cells were also present in wild-type
lesions (Fig. 6 I). In contrast, clusters or “nests” of CD41
cells were observed in many of the lesions in gld spinal
cords (Fig. 6 H), and were often surrounded by CD11b1
cells (Fig. 6 G). The correlation between the presence of
these T cell nests and recipient genotype was not absolute,
in that CD41 cell clusters were not found in all spinal cord
sections from gld recipients and small nests were observed
in some sections of wild-type spinal cord. However, there
was a direct correlation between the severity (and possibly
the duration) of chronic disease in affected recipient ani-
mals, regardless of their genotype, and the average number
of CD41 T cell nests (Table III). Taken in conjunction
with results from our adoptive transfer experiments, we be-
lieve that the presence of many CD41 cells in gld recipients
is indicative of an impaired ability of these FasL-deficient
animals to curtail expansion of activated, Fas1 lymphocytes.
A combined immunohistochemical and TUNEL analysis of
actively induced EAE lesions from wild-type and lpr mice
has also implicated a Fas-mediated lytic mechanism for the
elimination of CD41 and CD81 T lymphocytes (Sabelko-
Downes, K.A., A.H. Cross, and J.H. Russell, manuscript in
preparation).
Discussion
The data presented here provide conclusive evidence
that a Fas-mediated lytic mechanism is involved in the
pathogenesis of EAE, as FasL-deficient lymphocytes trans-
fer attenuated disease, whereas the absence of Fas in recipi-
ent animals dramatically attenuated the development of
clinical signs of EAE induced by encephalitogenic, FasL-
expressing lymphocytes. The pathogenic, Fas-dependent lytic
interaction presumably occurs between FasL1 lymphocytes
and Fas-expressing targets in the CNS. FasL-deficient gld
lymphocytes could transfer EAE to some gld mice, and an
lpr recipient did develop clinical disease. This, along with
our previous study in which EAE was actively induced in
some lpr and gld mice (11), demonstrates that although a
Fas-dependent lytic mechanism is important, the pathogen-
esis of EAE is not solely dependent upon Fas.
The reported role for Fas in diabetes (22, 23) has re-
cently been questioned, as the adoptive transfer of diabeto-
genic lymphocytes into NOD.lpr mice resulted in a partial
rejection of the donor cell population (24). The authors
suggested that an interaction between FasL1 recipient cells
and Fas1 donor lymphocytes contributed to donor cell re-
jection by the NOD.lpr mice. We believe that this process
only poses a potential problem when the lpr allele is present
in animals whose genetic background predisposes them to
develop accelerated lymphoproliferative and autoimmune
disease. C57BL/6 and B10.PL mice do not fall into this
Table III. Nests of CD41 T Cells Are Predominantly Found in Spinal Cord Sections from Chronically Affected gld Recipients of 
Conventional Wild-type T Cells*
Recipient
genotype
Peak clinical
score
Clinical score at
time of death
Duration of clinical signs
of EAE (days)‡
Mean number of nests per spinal
cord cross-section§
B10.PL 2 0 19 0
B10.PL 2 0 27 0.75 6 0.96
gld 44 7 3 i 2.8 6 1.5
gld 42 7 3 i 2.8 6 1.9
gld 42 4 3 i 1.6 6 2.1
gld 31 4 3 i  1 6 1.7
gld 2 0 30 0
*EAE was induced as described in Fig. 1.
‡All animals were killed at 67 or 68 d after cell transfer, except gld/gld mice exhibiting clinical signs of disease for 73 d, which were killed at 94 d af-
ter cell transfer.
§Nests or clusters of .10 immediately adjacent CD41 cells were counted in 4–5 representative lower spinal cord cross-sections per mouse. The av-
erage number of clusters per cross-section 6 SD is shown for each animal.
iAnimals were still sick at termination of experiment.1203 Sabelko-Downes et al.
category, as the severe lymphoproliferative disease associ-
ated with the lpr mutation does not develop until animals
are z12–16 wk old (Sabelko-Downes, K.A. and J.H. Rus-
sell, unpublished observation). B10.PL and congenic lpr and
gld donor and recipient animals used in all of our experiments
were 6–8 wk old at the time of transfer. Thus, donor lym-
phocytes were transferred into recipient mice at least 4–6 wk
before the onset of severe lymphoproliferative disease. This
issue was also addressed by the experiment in which we de-
tected comparable levels of donor cells in the spleens of wild-
type and lpr recipients 3 and 5 d after cell transfer (Fig. 3).
Two additional experiments substantiate a role for Fas in
the pathogenesis of EAE. First, we (11) and others (12, 13)
have previously observed a difference in the severity of ac-
tively induced EAE between young (6–8 wk old) wild-
type and lpr mice on the B10.PL and C57BL/6 back-
grounds, respectively. Furthermore, in our study we were
able to transfer Fas-deficient lymphocytes into wild-type or
lpr mice and again we found that the absence of Fas in the
host mitigated the clinical signs of EAE (Fig. 2 B and Table
II). In this transfer the donor lpr lymphocytes could not
have been eliminated by FasL1 cells in the lpr recipients. It
is highly unlikely that the lack of EAE we have observed in
lpr recipients results from rejection of the donor lympho-
cyte population. Thus, the data in this paper support our
conclusion that a Fas-dependent mechanism is important
for the pathogenesis of EAE.
Our adoptive transfer experiments have also revealed a
role for a Fas-dependent lytic interaction in the recovery
from disease, as most FasL-deficient gld recipients devel-
oped chronic EAE. This Fas-dependent regulatory mecha-
nism apparently involves targets, and possibly effectors, that
are distinct from those involved in the Fas-mediated lytic
mechanism that helps to initiate EAE. The FasL-expressing
effector cells are host-derived, and could be resident CNS
cells or cells recruited into the CNS during inflammation,
whereas the targets are likely to be activated, Fas1 lympho-
cytes infiltrating the CNS. Wild-type recipients of trans-
genic lpr lymphocytes did not develop prolonged signs of
EAE. This suggests that a population of activated lympho-
cytes that are targets of Fas-mediated lysis during the recov-
ery from EAE may be host-derived cells recruited into the
CNS during the course of disease. In gld recipients, these
Fas1 host-derived cells and any donor lpr lymphocytes
present in the CNS could help establish chronic EAE.
We have found that Fas-deficient CD41 lymphocytes
were able to invade the CNS and that severe inflammation
developed in the CNS of FasL-expressing wild-type hosts.
This indicates that FasL does not provide a primary defense
against infiltration of activated T cells (i.e., immune privi-
lege). However, our adoptive transfer experiments suggest
that once FasL is induced on cells recruited into or residing
within the CNS by inflammation, it may function in a
mechanism analogous to that invoked for immune privi-
lege (25, 26) to limit the expansion of activated T cell pop-
ulations in the CNS. In gld recipients, infiltration of the
CNS does not induce functional FasL, and consequently
lymphocytes can accumulate and continue to damage the
CNS. Although Fas-dependent T cell suicide could also
occur, we were unable to ascertain the relative contribu-
tion of this autonomous lytic interaction to the elimination
of the infiltrating T cell population from the experiments
described here. Nevertheless, any potential treatment for
MS designed to disrupt Fas-mediated lytic interactions
must take into consideration this dual role for FasL in EAE.
This paper provides in vivo functional evidence impli-
cating both donor lymphocytes and host-derived elements
as FasL1 effectors that contribute to the progression of
EAE. It further suggests the host CNS is a major source of
Fas-expressing targets. Although this study has not deter-
mined the specific cell types that serve as targets and effec-
tors of Fas-mediated lytic interactions in EAE, we can
speculate as to their identity. It is likely that oligodendro-
cytes are the Fas1 targets of myelin disruption in EAE, as
they have been identified as Fas-expressing cells in MS le-
sions (6–8) and are able to express Fas and serve as lytic tar-
gets in vitro (6). FasL has been detected on glial cells (7),
and in particular microglia (6, 8), in MS lesions, making
these resident cells of the CNS candidate effectors of Fas-
dependent lysis. Macrophages recruited into the CNS dur-
ing EAE are also potential effectors of Fas-mediated death.
In sum, these experiments have described both a novel
pathogenic mechanism and a regulatory process of T cell–
mediated autoimmune disease in the CNS, each mediated
by an interaction between Fas and its ligand. We propose
the following model to describe the dual role of Fas-depen-
dent lytic interactions in the initiation of and recovery from
EAE. After an initial stimulation, the activated and differ-
entiated T cell enters the CNS, encounters its antigen pre-
sented by a resident APC (e.g., endothelial cells, microglia,
astrocytes) and is activated for the second time. At this
point, the Th1 cell can function as an effector and/or target
of Fas-dependent lysis. The effector T cell also secretes pro-
inflammatory cytokines, including IFN-g and LT/TNF-a,
which can enhance expression of MHC molecules and
promote cytokine/chemokine production by microglia and
astrocytes (27–29). IFN-g and TNF-a can also induce ex-
pression of Fas (30–32) or FasL (33, 34) on various cell
types. Consequently, they may contribute to the pathogen-
esis of EAE by augmenting expression of this lytic receptor
on oligodendrocytes, for example, and/or by inducing ex-
pression of its ligand on microglia or astrocytes. Although
the relative contributions of the effector cell populations is
not clear, it is likely that FasL expressed by infiltrating lym-
phocytes plays a primary role in the initiation of disease, as
it seems the FasL expressed on cells residing within or re-
cruited into the CNS must be induced by products of the
inflammatory cascade. However, upon induction, FasL ex-
pressed on cells present in the CNS may function in the
pathogenic process, and certainly becomes a major partici-
pant in the recovery from EAE. The balance achieved be-
tween the Fas-mediated death of CNS cell targets, which
would enhance the progression of EAE, and the Fas-depen-
dent death of infiltrating T cells, which would contribute
to remission of disease, will in part determine the clinical
manifestations of EAE.1204 Dual Role for FasL in Experimental Allergic Encephalomyelitis
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